Hereditary non‐polyposis colorectal cancer and the role of <i>hPMS2</i> and <i>hEXO1</i> mutations
Ella R. Thompson(Peter MacCallum Cancer Centre), Rodney J. Scott(New South Wales Department of Health), AD Spigelman(University of Newcastle Australia), Cliff Meldrum(New South Wales Department of Health), L. Thomas(University of Liverpool), Renee Crooks(John Hunter Hospital), Mary McPhillips(John Hunter Hospital)
Cited by 71
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2016|1k
Inflammatory subtypes in asthma: Assessment and identification using induced sputum
|Respirology|2006|939